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glutamyl transpeptidase and mean corpuscular volume, which were all signif-
icantly associated with cancer mortality, the hazard ratio (HR) for cancer mor-
tality in subjects with non HDL-cholesterol < 3.5 mmol/L was 2.83 [95%
confidence interval: 1.73-4.62]. The adjusted HR in subjects with HDL-cho-
lesterol < 0.9 mmol/L was 2.87 [1.63-5.06]. The adjusted HR in subjects on
lipid-lowering drug as compared to untreated subjects was 0.31 [0.11-0.85].
Conclusion: In this cohort mainly composed of primary prevention sub-
jects, low HDL- and low non HDL-cholesterol levels were associated with
increased cancer mortality, whereas risk of cancer death was reduced in users
of lipid-lowering drugs. This suggests that the impact of low cholesterol on
cancer risk may be different in subjects with spontaneously low levels and in
those for whom cholesterol is lowered by lipid-lowering drugs.
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Introduction: Regular light to-moderate wine consumption, defined as 1–
3 drinks/day, is associated with a lower risk of cardiovascular disease. More-
over, half of the cardiovascular benefit of wine consumption would be attrib-
utable to its High density lipoprotein-cholesterol (HDL-C) rising effect. The
aim of this prospective study was to investigate the association between mod-
erate wine consumption and HDL-C levels in patients who survived an acute
myocardial infarction (AMI).
Methods: From the French regional RICO survey, 920 consecutive
patients surviving an AMI were included between the 1st January and the 31st
december 2005. At one year follow-up, patients were asked to report their
wine consumption, using a questionnaire and examination of serum lipids was
performed. Associations of demographic, clinical, and lifestyle risk-factors
with HDL-C levels were assessed with multivariate analysis.
Results: Patient consuming 1-3 drink/day of wine had higher HDL-C
levels (respectively, 0.47(0.38-0.56) vs 0.43(0.35-0.53) mg/dL, (p=0.026)),
and lower CRP concentrations (2(1-5) vs 4(2-7) mg/L (p=0.01)), than non or
high-drinkers (0 or >4 drink/day). No difference was reported for triglycerides
or LDL-C levels in the two groups. In univariate analyses, CRP levels, dia-
betes, smoking and body mass index (BMI) were negatively associated with
high HDL-C (> 40 mg/dL in men and >50 mg/dL in women). In contrast,
female, physical activity and moderate wine intake were positively associated
with HDL-C. In multivariate analyses, BMI (OR (95%CI) (0.91(0.87-0.96)),
physical activity (OR(95%CI) (1.23(1.07-1.41)) and moderate wine intake
(OR(95%CI) (1.84(1.22-3.73)) were associated with high HDL-C.
Conclusion: These data suggest that a moderate wine intake is associated
with elevated levels HDL-C levels. This association may participate to the
beneficial effect of moderate wine intake on cardiovascular disease.
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Introduction: Cardiovascular diseases are the leading cause of mortality in
the western countries at the same time they are beginning to appear with
increasing frequency in developing countries. The Tunisian epidemiological
data on cardiovascular disease in the hospital environment are scarce. The aim
of this study was to evaluate the frequency of cardiovascular risk factors and
their association in patients hospitalised for coronary disease in coronary care
units at Rabta, Charles Nicolle, Habib Thameur, Tahar Maamouri, Menzel
Bourguiba and Military hospitals, over the period 1994-1998.
Patients and methods: The clinical features of 7164 patients (72.2% men
with a mean age of 59 years, 3408 myocardial infarction, 3756 unstable
angina) on hospital admission were analysed.
Results: The prevalence of hypertension (blood pressure ≥ 140/90 mmHg)
was 41.4%. There is a statistically significant difference in the prevalence of
hypertension (p<0.001) between men (33.4%), and women (62.1%). The prev-
alence of diabetes (glycemia ≥ 1.26 g/l) was 44.8%. The prevalence was
higher in women (53.3%) than in men (41.1%, p<0.001). The prevalence of
obesity (BMI ≥ 30 kg/m2) (18.8%) was higher in women (29% vs. 14.9% in
men, p<0.001). The incidence of dyslipidemia (CT > 2.5 g/l and/or TG > 1.5
g/l) was 44.9%. The percentage was higher in women (48.2%) than in men
(43.3%, P< 0.001). The prevalence of smoking was 64.3%, with a statistically
significant difference between men (84.4%) and women (12.2%). Twenty four
percent of the patients had one cardiovascular risk factor, 32% had two, 25%
had three factors and 13% had four or more factors.
Conclusion: With this risk factor profile Tunisia has to implement a
national strategy of primary prevention and heart health promotion in addition
to the efforts recently made in secondary prevention of some chronic disease
such as hypertension, diabetes and smoking.
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Purpose: To assess ten-year change in the prevalence of the metabolic syn-
drome among French subjects using the National Cholesterol Education Pro-
gram (NCEPATP III) criteria with the American Diabetes Association’s
updated definition of elevated fasting glucose (≥ 1g/l). Two definitions were
assessed, one taking into account a treatment for hypertension and for elevated
triglycerides or reduced high-density lipoprotein (HDL) cholesterol (Met2)
and the other not (Met).
Methods: Two cross-sectional representative surveys of the general popu-
lation were carried out in 1996 and 2006 in three French areas: the Urban
Community of Lille in the North, the districts of Bas-Rhin in the East and of
Haute-Garonne in the South. Inhabitants aged 35-64 years were randomly
recruited from electoral rolls after stratification on gender, 10 year-age group
and town size. Standardized sociodemographic, medical and anthropometric
data were collected and a fasted blood sample was analysed centrally. Preva-
lences in the age group 35-64 years were adjusted for the French population
of year 2000.
Results: A total of 3405 subjects in 1996 and 3554 subjects in 2006 were
included in the analyses. In both years the metabolic syndrome was more
common among men than among women and increased with age. The age-
adjusted prevalences [95% confidence interval] of Met were 26.3% [23.9-
28.7] and 18.1% [16.1-20.1] in 1996 and 23.1% [20.9-25.3] and 15.1%
[13.3-16.9] in 2006, in men and women respectively. The equivalent results
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for Met2 were 30.5%, 21.5%, 24.8% and 16.4%. The age-adjusted preva-
lence of Met (Met2) decreased significantly by 12.1% (18.7%) in men and
16.6% (23.7%) in women. Of the five Met criteria, decreasing trends were
observed in the prevalence of high blood pressure, elevated fasting glucose,
low HDL cholesterol. By contrast, prevalence of abdominal obesity appeared
unchanged whereas prevalence of hypertriglyceridemia increased signifi-
cantly.
Conclusions: In France, the prevalence of the metabolic syndrome tended
to decline in the last decade in both genders, particularly in women.
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Purpose: Assessment of cardiovascular risk level is uniformly recom-
mended for appropriate management of risk factors. Risk of all-cause
death is seldom considered in available algorithms. We aimed to establish
an updated algorithm to predict 10-year all-cause mortality in apparently
healthy subjects.
Methods: Our analysis was based on the Third French MONICA Cross-
sectional survey on cardiovascular risk factors (1995-1996). Participants aged
35-64 were randomly recruited from French polling lists. Subjects with a his-
tory of atherosclerotic cardiovascular disease or severe chronic disease were
excluded. Vital status was obtained 10 years after inclusion.
Results: There were 3208 participants and 156 deaths over the 10-year
period. Determinants significantly and independently associated with 10-year
all-cause death were living area (Hazard Ratio=1.04 [95% confidence interval:
0.67-1.61]
 
for East, HR=1.76 [1.21-2.58] for North, versus South-west of
France), age (HR=1.64 [1.02-2.64] for 45-54, HR=3.89 [2.49-6.09] for 55-64
vs 35-44 years), male gender (HR=2.11 [1.48-3.01]), no high school comple-
tion (HR=1.57 [1.05-2.33]), smoking (HR=2.61 [1.45-4.70] for smoking < 15
packs-years
,
 HR=2.90 [2.01-4.17] for ≥ 15 packs-years,
 
vs non-smoking), sys-
tolic blood pressure ≥ 160 mmHg (HR= 1.57 [1.03-2.39]), LDL-cholesterol ≥
5.2 mmol/l (HR=1.62 [1.01-2.61]) and diabetes (HR=1.62 [1.10-2.37]). We
developed an algorithm and established score sheets to estimate absolute 10-
year risk of death, for a given subject, according to baseline characteristics.
For example, a non diabetic, heavy smoker, 46 year old man, living in South-
west of France, who did not complete high school, with LDL-cholesterol ≥ 5.2
mmol/l and systolic blood pressure < 160 mmHg, has a 17% 10-year risk of
death.
Conclusions: This prediction algorithm is a simple tool adapted to a Euro-
pean population to guide practitioners towards a more or less aggressive man-
agement of risk factors in apparently healthy subjects.
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Background: Epidemiological studies are needed to evaluate the impact of
the recent changes in clinical practice on the incidence of cardioembolic stroke
with atrial fibrillation (CE/AF stroke).
Methods: Overall ischemic strokes were prospectively ascertained in the
population-based registry of Dijon, France (150,000 inhabitants), from 1985 to
2006. We evaluated trends in incidence rates, risk factors, prestroke therapy,
and survival in CE/AF stroke.
Results: 3064 ischemic strokes including 572 (18.7%) CE/AF strokes were
recorded. Over the 22 years, a decrease in the incidence of overall CE/AF
stroke was noted ([IRR] 0.9858, 95% CI 0.9731-0.9986; p=0.03). We
observed a higher prevalence of previous AF, previous myocardial infarction,
and patients aged >70 years in CE/AF strokes (p<0.0001) whereas hypercho-
lesterolemia was more prevalent in other ischemic strokes (p=0.003). A signif-
icant increase in the use of anticoagulants and antiplatelet agents was noted,
and was particularly pronounced for CE/AF strokes with previous AF. For CE/
AF strokes, survival rates were 72% at 1 month (95% CI 0.68-0.76), 52% at 1
year (95% CI 0.48-0.56), and 43% (95% CI 0.39-0.48) at 2 years, and
remained lower than those of other ischemic strokes.
Conclusions: The decrease in the incidence of CE/AF stroke may reflect
the increase in the utilization of antithrombotic therapy in patients with AF,
but the use of such therapies will have to increase further because of the
expected ageing of the population in coming years.
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Purpose: Although statins are the cornerstone of cardiovascular (CV) pre-
vention, patients (pts) treated with statins remain at substantial CV risk. Per-
sistent lipid abnormalities, among other CV risk factors (RF), are likely to
contribute to this residual CV risk. The objective of the study was to assess
the prevalence of dyslipidemia in high-risk pts receiving statin therapy.
Methods: This French cross-sectional study was conducted by 741 general
practitioners or specialists within the international DYSIS study performed in
12 countries (Europe, Canada). Pts were ≥45 years-old, on statin therapy for
≥3 months with available lipid values. A clinical examination and the
recording of the latest lipid values on statin were performed. High-risk pts
included pts with CV disease, or pts with diabetes and 2 or more RF or
patients with a 10 years risk of coronary event > 20%.
Results: Among 4335 pts included in DYSIS, 2669 (61.6%) were at high
risk. Data for this group of pts are presented hereafter. Their mean age was
66.9 ± 9.8 years, 72.6% were male, 78.6% had hypertension, 48.2% had dia-
betes, 29.9% had family history of premature CV disease and 13.3% were
smokers. CHD was present in 55.1% of pts, cerebrovascular disease in 12.2%
and peripheral artery disease in 21.7%. 30.5% were obese and 66.7% had met-
abolic syndrome.
Conclusion: Persistent dyslipidemia is still prevalent in high risk statin-
treated pts in France, with high proportions of pts not at LDL-C goal with low
HDL-C and/or elevated triglycerides. An intensive and comprehensive lipid
management in this population would decrease the prevalence of lipid abnor-
malities and might contribute to further decrease the CV risk.
Table. Percentage of high risk statin-treated pts with different lipid abnor-
malities (n=2669) 
 
LDL-C 
not at goal 
(> 1 g/l)
Low HDL-C 
(<0.40 g/l)
Elevated TG 
(>1.5 g/l)
LDL-C 
not at goal 
+ HDL-C 
<0.40 g/l 
and/or 
TG>1.5 g/l
High CV risk 
pts (%)
52.4 23.0 38.2 25.7
